Gwarzo Ibrahim, Coleman Keli D, McKinley Kenneth, Ellison Angela M, Alpern Elizabeth R, Corboy Jacqueline, Hariharan Selena, Topoz Irina, Wurtz Morgan, Nielsen Blake, Cook Lawrence J, Morris Claudia R, Brandow Amanda M, Campbell Andrew D, Liem Robert I, Nuss Rachelle, Quinn Charles T, Thompson Alexis A, Villella Anthony, King Allison A, Baumann Ana, Frankenberger Warren, Brousseau David C
Department of Pediatrics, Nemours Children's Health, Wilmington, Delaware.
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
JAMA Pediatr. 2025 Sep 2. doi: 10.1001/jamapediatrics.2025.2967.
Guidelines for the timely emergency department (ED) administration of opioids for acute sickle cell disease (SCD) pain lack clear evidence showing associations with reduced hospitalizations.
To evaluate the associations between the timely administration of multiple opioid doses during uncomplicated SCD pain episodes in children and hospitalization.
DESIGN, SETTING, AND PARTICIPANTS: This multisite cross-sectional study used data from the Pediatric Emergency Care Applied Research Network Registry. Included were 12 pediatric EDs from children's hospitals with comprehensive SCD centers across the US. ED visits by children younger than 19 years with uncomplicated SCD pain at any of the 12 sites between January 1, 2019, and December 31, 2021, were included. Primary diagnosis codes were used to identify visits for SCD pain; visits with any other SCD complication were excluded. Initial data analysis was conducted from April 2024 to April 2025, including revisions. After-revision analyses were done between May and June of 2025.
The 2 exposures of interest were as follows: (1) time from ED arrival to first opioid administration (dichotomized as ≤60 minutes of arrival vs >60 minutes from arrival) and (2) time interval between the first and the second opioid administration (dichotomized in separate analyses as ≤30 minutes vs >30 minutes, ≤45 minutes vs >45 minutes, and ≤60 minutes vs >60 minutes).
The primary outcome was hospitalization at the end of an ED visit.
A total of 2538 patients (mean [SD] age, 12.0 [5.0] years; 1293 male [50.9%]) were included in this study. Of 9233 ED visits, 5023 (54.4%) resulted in hospitalization. First-dose timeliness of opioid administration evaluated alone was associated with decreased hospitalizations (odds ratio [OR], 0.84; 95% CI, 0.75-0.95). Evaluating combined first- and second-dose timeliness of opioid administration for the 7853 visits (85.1%) with 2 or more opioid doses, first-opioid timeliness was associated with reduced odds of hospitalization, even when the second dose was outside 30 minutes (OR, 0.85; 95% CI, 0.74-0.98) or 45 minutes (OR, 0.84; 95% CI, 0.72-0.97). First-dose timeliness combined with a second dose within 30-minute (OR, 0.62; 95% CI, 0.52-0.75), 45-minute (OR, 0.70; 95% CI, 0.59-0.83), and 60-minute (OR, 0.78; 95% CI, 0.67-0.92) intervals achieved the lowest odds of hospitalization.
This cross-sectional study found that timely receipt of opioids was associated with a reduction in hospitalizations for SCD pain. The largest decrease in hospitalization was achieved with the first dose within 60 minutes and the second dose within 30 minutes; however, longer second-dose durations were associated with reduced hospitalizations.
关于急诊科及时给予阿片类药物治疗急性镰状细胞病(SCD)疼痛的指南缺乏明确证据表明其与减少住院率相关。
评估儿童单纯性SCD疼痛发作期间多次给予阿片类药物的及时性与住院之间的关联。
设计、地点和参与者:这项多中心横断面研究使用了儿科急诊护理应用研究网络登记处的数据。纳入了美国各地设有综合性SCD中心的儿童医院的12个儿科急诊科。纳入了2019年1月1日至2021年12月31日期间在12个地点中任何一个地点就诊的19岁以下患有单纯性SCD疼痛的儿童。使用主要诊断代码来识别SCD疼痛就诊;排除伴有任何其他SCD并发症的就诊。初始数据分析于2024年4月至2025年4月进行,包括修订。修订后的分析于2025年5月至6月进行。
两个感兴趣的暴露因素如下:(1)从急诊科就诊到首次给予阿片类药物的时间(分为就诊后≤60分钟与就诊后>60分钟),以及(2)首次与第二次给予阿片类药物之间的时间间隔(在单独分析中分为≤30分钟与>30分钟、≤45分钟与>45分钟、≤60分钟与>60分钟)。
主要结局是急诊科就诊结束时的住院情况。
本研究共纳入2538例患者(平均[标准差]年龄,12.0[5.0]岁;1293例男性[50.9%])。在9233次急诊科就诊中,5023次(54.4%)导致住院。单独评估阿片类药物给药的首剂及时性与住院率降低相关(比值比[OR],0.84;95%置信区间,0.75 - 0.95)。对于7853次(85.1%)接受2剂或更多剂阿片类药物的就诊,评估阿片类药物给药的首剂和第二剂联合及时性时,即使第二剂在30分钟(OR,0.85;95%置信区间,0.74 - 0.98)或45分钟(OR,0.84;95%置信区间,0.72 - 0.97)之外,首剂及时性仍与住院几率降低相关。首剂及时性与30分钟(OR,0.62;95%置信区间,0.52 - 0.75)、45分钟(OR,0.70;95%置信区间,0.59 - 0.83)和60分钟(OR,0.78;95%置信区间,0.67 - 0.92)内的第二剂联合使用时,住院几率最低。
这项横断面研究发现,及时接受阿片类药物与SCD疼痛住院率降低相关。在60分钟内给予首剂且在30分钟内给予第二剂时,住院率下降幅度最大;然而,第二剂给药间隔时间延长也与住院率降低相关。